Incyclix Bio nets $30m Series B
Incyclix Bio, a next-generation cell cycle control company, has secured $30 million in Series B financing.
Incyclix Bio, a next-generation cell cycle control company, has secured $30 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination